

Buy EUR 4.70	(EUR 4.50)	Value Indicators: DCF:	EUR 4.70	Warburg Risk Score: Balance Sheet Score: Market Liquidity Score:	1.9 3.8 0.0	Description: Cyan specializes in network and fraud prevention.	security
		Market Snapshot:	EUR m	Shareholders:		Key Figures (WRe):	2025e
		Market cap:	54.7	Freefloat	34.00 %	Beta:	1.1
Price	EUR 2.52	No. of shares (m):	21.7	Inst. Investors	66.00 %	Price / Book:	1.8 x
Upside	86.5 %	EV:	53.1			Equity Ratio:	90 %
		Freefloat MC:	18.6				
		Ø Trad. Vol. (30d):	8.51 th				

First positive EBITDA after transformation; FY 25 guidance increased

in Mio. EUR	H1/25	H1/25e	ΔWR	H1/24	yoy	2025e	2024	yoy
Sales	4.4	4.1	7.3%	3.2	37.0%	9.1	7.1	28.8%
EBITDA	0.5	-0.3	-	-1.1	-	0.5	-1.5	-
margin	11.1%	-		-		6.0%	-	
EBIT	-0.3	-1.2	-	-2.4	-86.4%	-1.3	-4.0	-67.2%
margin	-	-		-		-	-	

Comment on Figures:

- Revenue: Sales continued to increase driven by existing customers and not yet including co-operation with Orange Romania and Odido announced during H1 25. Odido is the first operator to roll out cyan's "Guard 360" product that protects against phishing, malware and other digital threats.
- EBITDA: Significant earnings improvement driven by strong revenue growth and stringent cost management.


Yesterday (25.09.2025) cyan AG published H1 25 figures, which showed solid revenue growth of +37% yoy to EUR 4.4m mainly driven by strong growth with existing customers. Furthermore, H1 EBITDA turned positive to EUR +490k which beat our estimate. Following solid results, the FY 25 guidance was increased.

- Financials: Revenue increased to EUR 4.4m / +37% (WRe: EUR 4.1m) primarily driven by contracts in Poland EUR 1.17m / +39.5% and other EMEA countries EUR 1.16m / +159% and based on existing customer contracts as the end-subscriber base grew by +24%. The share of recurring revenue increased to 97% in H1 25 with 95% in H1 24 and FY 24. Personnel expenses were EUR 290k lower than in H1 24 and contributed to cyan's positive result. Net operating cash flow improved significantly to EUR 1.26m (H1 24: EUR -3.29m including EUR -2m from divested OSS/BSS segment) contributing to H1 25 cash levels of EUR 1.87m.
- Guidance 25e: The 2025 guidance was increased to revenue range of EUR 8.8m–9.2m (previously: EUR 8.4–9.2m) and slightly positive EBITDA 25e (previously: significant EBITDA improvement).
- Valuation: Following an update of our estimates, the DCF-based fair value increases to EUR 4.70.
- Our view: Strong operational results and cyan's first positive EBITDA result since the business transformation confirm our investment case. The existing group contract with Orange Group was extended for another three years, which secures the business cooperation and therefore revenue streams going forward. cyan entered new co-operation agreements with Orange Romania and Odido for its new Guard 360 product. This should help to achieve the updated guidance for FY 25e. Overall, we confirm our Buy rating.

Changes in E FY End: 31.12. in EUR m	Estimates: 2025e (old)	+/-	2026e (old)	+/-	2027e (old)	+/-
Sales	9.1	0.0 %	11.0	0.0 %	13.1	0.0 %
EBITDA	-0.5	n.m.	1.0	21.2 %	2.2	3.0 %
EBIT	-2.3	n.m.	-0.8	n.m.	0.3	21.3 %

Comment on Changes:

- Revenue: Our revenue estimates remain stable. FY 25e revenue is expected at the upper end of the guidance range of EUR 8.8–9.2m.
- EBITDA: Higher EBITDA for the coming years. FY 25e EBITDA is increased in line with the guidance and driven by better than assumed personnel costs. However, personnel costs are assumed to increase as of H2 25 due to one-offs in H1 25 and higher headcount going forward.




Rel. Performance vs So	ale All Share
1 month:	8.0 %
6 months:	-41.2 %
Year to date:	-22.2 %
Trailing 12 months:	-4.1 %

Company events:

FY End: 31.12. in EUR m	CAGR (24-27e)	2021	2022	2023	2024	2025e	2026e	2027e
Sales	22.6 %	8.5	3.8	4.7	7.1	9.1	11.0	13.1
Change Sales yoy		-60.2 %	-55.2 %	24.0 %	50.4 %	28.8 %	20.4 %	19.0 %
Gross profit margin		27.3 %	76.7 %	73.2 %	81.8 %	86.0 %	83.0 %	83.0 %
EBITDA	-	-12.3	-4.4	-4.5	-1.5	0.5	1.3	2.2
Margin		-145.2 %	-114.8 %	-94.8 %	-20.7 %	6.0 %	11.5 %	17.0 %
EBIT	-	-18.1	-7.0	-7.0	-4.0	-1.3	-0.6	0.4
Margin		-212.9 %	-184.3 %	-148.6 %	-55.8 %	-14.2 %	-5.3 %	2.8 %
Net income	-	-13.9	-14.7	-20.6	-3.7	-0.3	0.4	1.4
EPS	_	-1.04	-0.87	-1.02	-0.18	-0.01	0.02	0.06
DPS	_	0.00	0.00	0.00	0.00	0.00	0.00	0.00
FCFPS		-0.61	-0.63	-0.13	-0.18	0.07	0.11	0.14
FCF / Market cap		-8.0 %	-26.0 %	-8.1 %	-8.2 %	2.8 %	4.3 %	5.7 %
EV / Sales		12.0 x	10.4 x	6.3 x	6.5 x	5.8 x	4.6 x	3.6 x
EV / EBITDA		n.a.	n.a.	n.a.	n.a.	96.8 x	40.3 x	21.5 x
EV / EBIT		n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	127.8 x
P/E		n.a.	n.a.	n.a.	n.a.	n.a.	126.0 x	42.0 x
FCF Potential Yield		-8.6 %	-30.3 %	-60.4 %	-2.6 %	2.9 %	4.5 %	6.8 %
Net Debt		-0.5	-1.6	-2.0	-0.1	-1.6	-3.9	-7.1
ROCE (NOPAT)		n.a.	n.a.	n.a.	n.a.	n.a.	1.4 %	4.9 %
Guidance:	Revenue: EU	R 8.8-9.2m;	slighlty positi	ve EBITDA				






Company Background

- Cyan is a cybersecurity provider specializing in network-integrated security and fraud prevention for telecom, finance, and global businesses.
- It offers Al-driven threat-detection, risk management, and seamless security integration to protect digital ecosystems.
- Founded in 2006, Cyan has a strong global presence and partners with major mobile network operators to provide scalable security solutions.

Competitive Quality

- Following the BSS/OSS divestment, Cyan is concentrating on expanding its presence in the cybersecurity industry.
- Cyan has established a strong foothold in telecom cybersecurity, providing white-label, network-integrated solutions.
- Its point-solution approach enables customers to access tailored, cost-effective cybersecurity services with less deployment complexity.





DCF model														
	Detaile	d forecas	st period				٦	Γransition	al period					Term. Value
Figures in EUR m	2025e	2026e	2027e	2028e	2029e	2030e	2031e	2032e	2033e	2034e	2035e	2036e	2037e	
Sales	9.1	11.0	13.1	15.6	18.5	22.1	26.2	30.2	34.7	39.9	43.9	46.1	47.7	
Sales change	28.8 %	20.4 %	19.0 %	19.0 %	19.0 %	19.0 %	19.0 %	15.0 %	15.0 %	15.0 %	10.0 %	5.0 %	3.5 %	3.5 %
EBIT	-1.3	-0.6	0.4	0.4	0.9	2.2	3.9	5.4	8.7	12.0	14.1	14.8	15.3	
EBIT-margin	-14.2 %	-5.3 %	2.8 %	2.5 %	5.0 %	10.0 %	15.0 %	18.0 %	25.0 %	30.0 %	32.0 %	32.0 %	32.0 %	
Tax rate (EBT)	77.1 %	170.5 %	-268.3 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	33.0 %	
NOPAT	-0.3	0.4	1.4	0.3	0.6	1.5	2.6	3.6	5.8	8.0	9.4	9.9	10.2	
Depreciation	1.8	1.8	1.8	1.6	1.9	1.8	1.3	0.9	1.0	1.2	1.3	1.4	1.4	
in % of Sales	20.2 %	16.8 %	14.1 %	10.0 %	10.0 %	8.0 %	5.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	
Changes in provisions	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Change in Liquidity from														
- Working Capital	1.5	0.4	0.6	0.7	0.7	-0.2	-0.5	-0.9	0.5	0.5	0.4	0.2	0.2	
- Capex	0.5	0.5	0.5	1.2	1.5	1.5	1.3	0.9	1.0	1.2	1.3	1.4	1.4	
Capex in % of Sales	5.5 %	4.5 %	3.8 %	8.0 %	8.0 %	7.0 %	5.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	3.0 %	
- Other	0.2	0.2	0.2	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	-0.7	1.2	1.9	-0.1	0.3	1.9	3.1	4.6	5.4	7.5	9.0	9.7	10.1	10
PV of FCF	-0.7	1.1	1.7	-0.1	0.2	1.3	1.9	2.6	2.8	3.6	4.0	4.0	3.8	76
share of PVs		2.00 %						23.60	6 %					74.34 %

Model parameter				Valuation (m)			
Derivation of WACC:		Derivation of Beta:		Present values 2037e	26		
				Terminal Value	76		
Debt ratio	5.00 %	Financial Strength	0.90	Financial liabilities	1		
Cost of debt (after tax)	4.2 %	Liquidity (share)	1.40	Pension liabilities	0		
Market return	8.25 %	Cyclicality	1.00	Hybrid capital	0		
Risk free rate	2.75 %	Transparency	1.00	Minority interest	0		
		Others	1.30	Market val. of investments	0		
				Liquidity	1	No. of shares (m)	21.7
WACC	8.67 %	Beta	1.12	Equity Value	102	Value per share (EUR)	4.70

Selis	ilivity va	liue per Sii	are (EUK)													
		Terminal (Growth								Delta EBIT	Γ-margin					
Beta	WACC	2.75 %	3.00 %	3.25 %	3.50 %	3.75 %	4.00 %	4.25 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.31	9.7 %	3.46	3.55	3.65	3.75	3.86	3.98	4.11	1.31	9.7 %	3.53	3.60	3.67	3.75	3.82	3.90	3.97
1.22	9.2 %	3.83	3.94	4.05	4.18	4.32	4.47	4.64	1.22	9.2 %	3.94	4.02	4.10	4.18	4.26	4.34	4.43
1.17	8.9 %	4.04	4.16	4.29	4.43	4.59	4.76	4.95	1.17	8.9 %	4.17	4.26	4.34	4.43	4.51	4.60	4.69
1.12	8.7 %	4.26	4.39	4.54	4.70	4.88	5.08	5.29	1.12	8.7 %	4.43	4.52	4.61	4.70	4.79	4.88	4.97
1.07	8.4 %	4.50	4.66	4.82	5.00	5.20	5.43	5.68	1.07	8.4 %	4.72	4.81	4.91	5.00	5.10	5.19	5.29
1.02	8.2 %	4.77	4.94	5.13	5.34	5.57	5.83	6.12	1.02	8.2 %	5.04	5.14	5.24	5.34	5.44	5.54	5.64
0.93	7.7 %	5.40	5.62	5.86	6.13	6.44	6.79	7.19	0.93	7.7 %	5.79	5.91	6.02	6.13	6.25	6.36	6.47

- Strength in the growing cybersecurity market should enable Cyan to achieve strong revenue growth.
- Highly scalable business model makes high EBIT margins appear possible.
- The higher depreciation expense from leased property in the detailed forecast period is adjusted for in Other.
- High depreciation rates stemming from PPA-related intangible assets are anticipated to decrease.

cyan AG



Valuation							
	2021	2022	2023	2024	2025e	2026e	2027e
Price / Book	1.4 x	0.9 x	1.0 x	1.6 x	1.8 x	1.7 x	1.6 x
Book value per share ex intangibles	1.37	0.88	0.19	0.10	0.28	0.40	0.55
EV / Sales	12.0 x	10.4 x	6.3 x	6.5 x	5.8 x	4.6 x	3.6 x
EV / EBITDA	n.a.	n.a.	n.a.	n.a.	96.8 x	40.3 x	21.5 x
EV / EBIT	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	127.8 x
EV / EBIT adj.*	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	127.8 x
P/FCF	n.a.	n.a.	n.a.	n.a.	36.3 x	23.2 x	17.5 x
P/E	n.a.	n.a.	n.a.	n.a.	n.a.	126.0 x	42.0 x
P / E adj.*	n.a.	n.a.	n.a.	n.a.	n.a.	126.0 x	42.0 x
Dividend Yield	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
FCF Potential Yield (on market EV)	-8.6 %	-30.3 %	-60.4 %	-2.6 %	2.9 %	4.5 %	6.8 %
*Adjustments made for: -							


Company Specific Items							
	2021	2022	2023	2024	2025e	2026e	2027e
Recurring revenue	n.a.	n.a.	4.2	4.2	n.a.	n.a.	n.a.
Non-recurring revenue	n.a.	n.a.	0.5	0.5	n.a.	n.a.	n.a.
Americas	n.a.	n.a.	1.2	0.0	n.a.	n.a.	n.a.
APAC	n.a.	n.a.	1.5	0.1	n.a.	n.a.	n.a.
EMEA	n.a.	n.a.	5.9	3.1	n.a.	n.a.	n.a.
Subscribers	n.a.	826160.0	1409588.0	2625494.0	n.a.	n.a.	n.a.
Operating cash flow	-8.1	-10.7	-2.6	-3.8	n.a.	n.a.	n.a.



Consolidated profit & loss							
In EUR m	2021	2022	2023	2024	2025e	2026e	2027e
Sales	8.5	3.8	4.7	7.1	9.1	11.0	13.1
Change Sales yoy	-60.2 %	-55.2 %	24.0 %	50.4 %	28.8 %	20.4 %	19.0 %
Increase / decrease in inventory	-0.8	0.0	0.0	0.0	0.0	0.0	0.0
Own work capitalised	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Sales	7.7	3.8	4.7	7.1	9.1	11.0	13.1
Material expenses	5.4	0.9	1.3	1.3	1.3	1.9	2.2
Gross profit	2.3	2.9	3.5	5.8	7.9	9.1	10.9
Gross profit margin	27.3 %	76.7 %	73.2 %	81.8 %	86.0 %	83.0 %	83.0 %
Personnel expenses	11.4	5.0	5.1	5.3	4.9	5.7	6.7
Other operating income	3.1	1.2	0.8	0.4	0.9	1.7	2.0
Other operating expenses	6.3	3.4	3.6	2.4	3.3	3.9	3.9
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	-12.3	-4.4	-4.5	-1.5	0.5	1.3	2.2
Margin	-145.2 %	-114.8 %	-94.8 %	-20.7 %	6.0 %	11.5 %	17.0 %
Depreciation of fixed assets	1.1	0.5	0.4	0.3	0.3	0.3	0.3
EBITA	-13.4	-4.9	-4.8	-1.8	0.2	0.9	1.9
Amortisation of intangible assets	4.6	2.1	2.2	2.1	1.5	1.5	1.5
Goodwill amortisation	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	-18.1	-7.0	-7.0	-4.0	-1.3	-0.6	0.4
Margin	-212.9 %	-184.3 %	-148.6 %	-55.8 %	-14.2 %	-5.3 %	2.8 %
EBIT adj.	-18.1	-7.0	-7.0	-4.0	-1.3	-0.6	0.4
Interest income	0.7	0.0	0.0	0.0	0.0	0.0	0.0
Interest expenses	0.2	0.1	0.0	0.0	0.0	0.0	0.0
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	-17.5	-7.1	-7.0	-4.0	-1.3	-0.6	0.4
Margin	-206.3 %	-186.7 %	-149.3 %	-55.9 %	-14.2 %	-5.3 %	2.8 %
Total taxes	-3.6	2.9	-1.7	-0.3	-1.0	-1.0	-1.0
Net income from continuing operations	-13.9	-10.0	-5.3	-3.7	-0.3	0.4	1.4
Income from discontinued operations (net of tax)	0.0	-4.7	-15.4	-0.1	0.0	0.0	0.0
Net income before minorities	-13.9	-14.7	-20.6	-3.7	-0.3	0.4	1.4
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	-13.9	-14.7	-20.6	-3.7	-0.3	0.4	1.4
Margin	-163.6 %	-387.4 %	-436.2 %	-52.4 %	-3.3 %	3.8 %	10.5 %
Number of shares, average	13.4	17.0	20.2	20.9	21.7	21.7	21.7
EPS	-1.04	-0.87	-1.02	-0.18	-0.01	0.02	0.06
EPS adj.	-1.04	-0.87	-1.02	-0.18	-0.01	0.02	0.06
*Adjustments made for:							

Guidance: Revenue: EUR 8.8-9.2m; slighlty positive EBITDA


Financial Ratios							
	2021	2022	2023	2024	2025e	2026e	2027e
Total Operating Costs / Sales	235.8 %	214.8 %	194.8 %	120.7 %	94.0 %	88.6 %	83.1 %
Operating Leverage	-1.1 x	1.1 x	0.0 x	-0.9 x	-2.3 x	-2.7 x	n.a.
EBITDA / Interest expenses	n.m.	n.m.	n.m.	n.m.	n.a.	n.a.	n.a.
Tax rate (EBT)	20.7 %	-40.8 %	24.6 %	7.8 %	77.1 %	170.5 %	-268.3 %
Dividend Payout Ratio	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Sales per Employee	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.





Consolidated balance sheet							
In EUR m	2021	2022	2023	2024	2025e	2026e	2027
Assets							
Goodwill and other intangible assets	54.5	30.6	28.1	25.9	24.9	23.9	22.9
thereof other intangible assets	22.8	8.0	5.6	3.5	2.5	1.5	0.5
thereof Goodwill	30.8	21.8	21.8	21.8	21.8	21.8	21.8
Property, plant and equipment	4.9	3.3	2.1	1.9	1.6	1.2	0.9
Financial assets	0.3	0.1	0.0	0.0	0.0	0.0	0.0
Other long-term assets	17.6	10.7	0.0	0.0	0.0	0.0	0.0
Fixed assets	77.3	44.8	30.2	27.8	26.5	25.1	23.8
Inventories	0.4	0.0	0.0	0.0	1.3	1.6	1.9
Accounts receivable	2.5	2.9	1.0	1.2	1.6	1.9	2.3
Liquid assets	8.5	5.3	2.9	0.8	2.3	4.7	7.8
Other short-term assets	7.1	7.4	9.6	2.8	2.8	2.8	2.8
Current assets	18.5	15.7	13.5	4.9	8.0	11.0	14.8
Total Assets	95.7	60.4	43.7	32.7	34.5	36.1	38.6
Liabilities and shareholders' equity							
Subscribed capital	13.4	17.0	20.2	20.2	20.2	20.2	20.2
Capital reserve	78.6	62.5	66.4	66.3	66.3	66.3	66.3
Retained earnings	-19.2	-33.9	-54.6	-58.3	-58.6	-58.2	-56.9
Other equity components	0.0	0.0	0.0	0.0	3.3	4.3	5.3
Shareholders' equity	72.8	45.6	32.0	28.1	31.1	32.5	34.9
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	72.8	45.6	32.0	28.1	31.1	32.5	34.9
Provisions	0.3	0.0	0.1	0.0	0.0	0.0	0.0
thereof provisions for pensions and similar obligations	0.3	0.0	0.1	0.0	0.0	0.0	0.0
Financial liabilities (total)	7.6	3.7	0.7	0.7	0.7	0.7	0.7
Short-term financial liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accounts payable	1.0	1.2	0.2	0.5	0.6	8.0	0.9
Other liabilities	14.0	9.9	10.7	3.3	2.0	2.0	2.0
Liabilities	23.0	14.8	11.7	4.6	3.4	3.6	3.7
Total liabilities and shareholders' equity	95.7	60.4	43.7	32.7	34.5	36.1	38.6


Financial Ratios							
	2021	2022	2023	2024	2025e	2026e	2027e
Efficiency of Capital Employment							
Operating Assets Turnover	1.3 x	0.8 x	-26.6 x	2.7 x	2.4 x	2.9 x	3.2 x
Capital Employed Turnover	0.1 x	0.1 x	0.2 x	0.3 x	0.3 x	0.4 x	0.5 x
ROA	-18.0 %	-32.9 %	-68.1 %	-13.4 %	-1.1 %	1.6 %	5.8 %
Return on Capital							
ROCE (NOPAT)	n.a.	n.a.	n.a.	n.a.	n.a.	1.4 %	4.9 %
ROE	-19.1 %	-24.9 %	-53.0 %	-12.4 %	-1.0 %	1.3 %	4.1 %
Adj. ROE	-19.1 %	-24.9 %	-53.0 %	-12.4 %	-1.0 %	1.3 %	4.1 %
Balance sheet quality							
Net Debt	-0.5	-1.6	-2.0	-0.1	-1.6	-3.9	-7.1
Net Financial Debt	-0.9	-1.6	-2.1	-0.1	-1.6	-3.9	-7.1
Net Gearing	-0.7 %	-3.6 %	-6.4 %	-0.2 %	-5.1 %	-12.1 %	-20.2 %
Net Fin. Debt / EBITDA	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.	n.a.
Book Value / Share	5.4	2.7	1.6	1.3	1.4	1.5	1.6
Book value per share ex intangibles	1.4	0.9	0.2	0.1	0.3	0.4	0.6





Consolidated cash flow statement							
In EUR m	2021	2022	2023	2024	2025e	2026e	2027e
Net income	-13.9	-14.7	-20.6	-3.7	-0.3	0.4	1.4
Depreciation of fixed assets	1.1	0.2	0.3	0.0	0.3	0.3	0.3
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	4.6	3.2	3.2	2.5	1.5	1.5	1.5
Increase/decrease in long-term provisions	0.0	0.1	0.1	0.1	0.0	0.0	0.0
Other non-cash income and expenses	0.0	-2.3	8.9	-0.1	0.0	0.0	0.0
Cash Flow before NWC change	-8.1	-13.4	-8.1	-1.3	1.5	2.3	3.2
Increase / decrease in inventory	0.0	0.0	0.0	0.0	-1.3	-0.3	-0.3
Increase / decrease in accounts receivable	0.0	-0.3	-1.2	0.2	-0.4	-0.3	-0.4
Increase / decrease in accounts payable	0.0	-1.4	2.1	-2.0	0.1	0.2	0.1
Increase / decrease in other working capital positions	0.0	4.4	4.7	-0.7	2.0	1.0	1.0
Increase / decrease in working capital (total)	0.0	2.7	5.6	-2.5	0.5	0.6	0.4
Net cash provided by operating activities [1]	-8.1	-10.7	-2.6	-3.8	2.0	2.9	3.6
Investments in intangible assets	0.0	0.0	0.0	0.0	-0.5	-0.5	-0.5
Investments in property, plant and equipment	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Payments for acquisitions	0.0	-0.8	-0.7	0.0	0.0	0.0	0.0
Financial investments	0.0	0.3	0.2	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.0	0.0	1.1	0.0	0.0	0.0
Net cash provided by investing activities [2]	0.0	-0.6	-0.5	1.1	-0.5	-0.5	-0.5
Change in financial liabilities	0.0	-4.0	-1.0	-0.3	0.0	0.0	0.0
Dividends paid	0.0	0.0	1.5	0.0	0.0	0.0	0.0
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	9.5	2.4	0.0	0.0	0.0	0.0
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net cash provided by financing activities [3]	0.0	5.5	2.9	-0.3	0.0	0.0	0.0
Change in liquid funds [1]+[2]+[3]	-8.1	-5.8	-0.1	-3.0	1.5	2.4	3.1
Effects of exchange-rate changes on cash	0.0	0.0	0.0	0.9	0.0	0.0	0.0
Cash and cash equivalent at end of period	-5.6	2.7	5.2	8.0	2.3	4.7	7.8

Financial Ratios							
	2021	2022	2023	2024	2025e	2026e	2027e
Cash Flow							
FCF	-8.1	-10.7	-2.6	-3.8	1.5	2.4	3.1
Free Cash Flow / Sales	-95.9 %	-282.7 %	-54.4 %	-53.5 %	16.5 %	21.5 %	23.8 %
Free Cash Flow Potential	-8.7	-12.0	-18.0	-1.2	1.5	2.3	3.2
Free Cash Flow / Net Profit	58.6 %	73.0 %	12.5 %	102.1 %	-506.2 %	570.6 %	227.2 %
Interest Received / Avg. Cash	13.2 %	0.1 %	0.3 %	0.9 %	0.0 %	0.0 %	0.0 %
Interest Paid / Avg. Debt	2.9 %	1.6 %	2.0 %	2.9 %	0.0 %	0.0 %	0.0 %
Management of Funds							
Investment ratio	0.0 %	0.0 %	0.0 %	0.0 %	5.5 %	4.5 %	3.8 %
Maint. Capex / Sales	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %
Capex / Dep	0.0 %	0.0 %	0.0 %	0.0 %	27.1 %	27.1 %	27.1 %
Avg. Working Capital / Sales	16.9 %	46.2 %	-6.5 %	-11.3 %	16.0 %	22.1 %	22.4 %
Trade Debtors / Trade Creditors	250.6 %	239.9 %	430.9 %	250.0 %	266.7 %	237.5 %	255.6 %
Inventory Turnover	15.2 x	22.1 x	n.a.	64.5 x	1.0 x	1.2 x	1.2 x
Receivables collection period (days)	107	277	81	63	64	63	64
Payables payment period (days)	68	495	70	139	171	156	148
Cash conversion cycle (Days)	62	-214	n.a.	-88	245	207	218



Source: Warburg Research Source: Warburg Research



LEGAL DISCLAIMER

This research report ("investment recommendation") was prepared by the Warburg Research GmbH, a fully owned subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It is intended solely for the recipient and may not be passed on to another company without their prior consent, regardless of whether the company is part of the same corporation or not. It contains selected information and does not purport to be complete. The investment recommendation is based on publicly available information and data ("information") believed to be accurate and complete. Warburg Research GmbH neither examines the information for accuracy and completeness, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these investment recommendations concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this investment recommendation, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this investment recommendation. Provided a investment recommendation is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This investment recommendation does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this investment recommendation are subject to change without notice. The views expressed in this research report accurately reflect the research analyst's personal views about the subject securities and issuers. Unless otherwise specified in the research report, no part of the research analyst's compensation was, is, or will be directly or indirectly related to the specific recommendations or views contained in the research report. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §85 OF THE GERMAN SECURITIES TRADING ACT (WPHG), MAR AND MIFID II INCL. COMMISSION DELEGATED REGULATION (EU) 2016/958 AND (EU) 2017/565

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Value Potential, NAV, Peer Group Comparison or Sum of the Parts Model (see also http://www.mmwarburg.de/disclaimer/disclaimer.htm#Valuation). The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

Additional internal and organisational arrangements to prevent or to deal with conflicts of interest have been implemented. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research GmbH in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg-Group.

All prices of financial instruments given in this investment recommendation are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin. M.M.Warburg & CO (AG & Co.) KGaA is additionally subject to the supervision of the European Central Bank (ECB).

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.



Additional information for clients in the United States

- 1. This research report (the "Report") is a product of Warburg Research GmbH, Germany, a fully owned subsidiary of M.M.Warburg & CO (AG & Co.) KGaA, Germany (in the following collectively "Warburg"). Warburg is the employer of the research analyst(s), who have prepared the Report. The research analyst(s) reside outside the United States and are not associated persons of any U.S. regulated broker-dealer and therefore are not subject to the supervision of any U.S. regulated broker-dealer.
- 2. The Report is provided in the United States for distribution solely to "major U.S. institutional investors" under Rule 15a-6 of the U.S. Securities Exchange Act of 1934 by CIC.
- 3. CIC (Crédit Industriel et Commercial) and M.M.Warburg & CO have concluded a Research Distribution Agreement that gives CIC Market Solutions exclusive distribution in France, the US and Canada of the Warburg Research GmbH research product.
- 4. The research reports are distributed in the United States of America by CIC ("CIC") pursuant to a SEC Rule 15a-6 agreement with CIC Market Solutions Inc ("CICI"), a U.S. registered broker-dealer and a related company of CIC, and are distributed solely to persons who qualify as "Major U.S. Institutional Investors" as defined in SEC Rule 15a-6 under the Securities Exchange Act of 1934.
- 5. Any person who is not a Major U.S. Institutional Investor must not rely on this communication. The delivery of this research report to any person in the United States of America is not a recommendation to effect any transactions in the securities discussed herein, or an endorsement of any opinion expressed herein.

Reference in accordance with section 85 of the German Securities Trading Act (WpHG) and Art. 20 MAR regarding possible conflicts of interest with companies analysed:

- Warburg Research, or an affiliated company, or an employee of one of these companies responsible for the compilation of the research, hold -1a share of more than 5% of the equity capital of the analysed company.
- Warburg Research, or an affiliated company, within the last twelve months participated in the management of a consortium for an issue in -2the course of a public offering of such financial instruments, which are, or the issuer of which is, the subject of the investment recommendation.
- Companies affiliated with Warburg Research manage financial instruments, which are, or the issuers of which are, subject of the investment -3recommendation, in a market based on the provision of buy or sell contracts.
- MMWB, Warburg Research, or an affiliated company, reached an agreement with the issuer to provide investment banking and/or investment services and the relevant agreement was in force in the last 12 months or there arose for this period, based on the relevant agreement, the obligation to provide or to receive a service or compensation - provided that this disclosure does not result in the disclosure of confidential business information.
- The company compiling the analysis or an affiliated company had reached an agreement on the compilation of the investment -5recommendation with the analysed company.
- Warburg Research, or an affiliated company, holds a net long position of more than 0.5% of the total issued share capital of the analysed -6acompany.
- Warburg Research, or an affiliated company, holds a net short position of more than 0.5% of the total issued share capital of the analysed -6bcompany.
- The issuer holds shares of more than 5% of the total issued capital of Warburg Research or an affiliated company. -6c-
- The company preparing the analysis as well as its affiliated companies and employees have other important interests in relation to the -7analysed company, such as, for example, the exercising of mandates at analysed companies.

This report has been made accessible to the company analysed.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
cyan AG	5	https://www.mmwarburg.com/disclaimer/disclaimer_en/DE000A2E4SV8.htm



INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARRIEG RESEARCH GMRH -	- ANALYSED RESEARCH UNIVERSE BY RATING
WANDONG NEGERINGII GIVIDII -	


Rating	Number of stocks	% of Universe
Buy	142	71
Hold	47	24
Sell	6	3
Rating suspended	4	2
Total	199	100

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... taking into account only those companies which were provided with major investment services in the last twelve months.

Rating	Number of stocks	% of Universe
Buy	39	76
Hold	9	18
Sell	1	2
Rating suspended	2	4
Total	51	100

PRICE AND RATING HISTORY CYAN AG AS OF 26.09.2025



Markings in the chart show rating changes by Warburg Research GmbH in the last 12 months. Every marking details the date and closing price on the day of the rating change.



EQUITIES			
Matthias Rode	+49 40 3282-2678		
Head of Equities	mrode@mmwarburg.com		
RESEARCH			
Henner Rüschmeier Head of Research	+49 40 309537-270 hrueschmeier@warburg-research.com	Simon Stippig Real Estate, Telco	+49 40 309537-265 sstippig@warburg-research.com
Stefan Augustin Cap. Goods, Engineering	+49 40 309537-168 saugustin@warburg-research.com	Marc-René Tonn Automobiles, Car Suppliers	+49 40 309537-259 mtonn@warburg-research.com
Christian Cohrs	+49 40 309537-175	Robert-Jan van der Horst	+49 40 309537-290
Industrials & Transportation Felix Ellmann	ccohrs@warburg-research.com +49 40 309537-120	Technology	rvanderhorst@warburg-research.com
Software, IT	fellmann@warburg-research.com		
Jörg Philipp Frey Retail, Consumer Goods	+49 40 309537-258 jfrey@warburg-research.com		
Marius Fuhrberg Financial Services	+49 40 309537-185 mfuhrberg@warburg-research.com		
Fabio Hölscher Automobiles, Car Suppliers	+49 40 309537-240 fhoelscher@warburg-research.com		
Philipp Kaiser	+49 40 309537-260		
Real Estate, Construction	pkaiser@warburg-research.com +49 40 309537-257		
Thilo Kleibauer Retail, Consumer Goods	tkleibauer@warburg-research.com		
Andreas Pläsier Banks, Financial Services	+49 40 309537-246		
Malte Schaumann	aplaesier@warburg-research.com +49 40 309537-170		
Technology	mschaumann@warburg-research.com		
Oliver Schwarz Chemicals, Agriculture	+49 40 309537-250 oschwarz@warburg-research.com		
INSTITUTIONAL EQUITY	SALES		
Klaus Schilling	+49 69 5050-7400		
Head of Equity Sales, Germany Tim Beckmann	kschilling@mmwarburg.com +49 40 3282-2665		
United Kingdom	tbeckmann@mmwarburg.com		
Jens Buchmüller Scandinavia. Austria	+49 69 5050-7415 jbuchmueller@mmwarburg.com		
Matthias Fritsch	+49 40 3282-2696	Leyan likbahar	+49 40 3282-2695
United Kingdom, Ireland	mfritsch@mmwarburg.com	Roadshow/Marketing	lilkbahar@mmwarburg.com
Roman Alexander Niklas Switzerland, Poland, Italy	+49 69 5050-7412 rniklas@mmwarburg.com	Antonia Möller Roadshow/Marketing	+49 69 5050-7417 amoeller@mmwarburg.com
Sascha Propp	+49 40 3282-2656	Juliane Niemann	+49 40 3282-2694
France	spropp@mmwarburg.com	Roadshow/Marketing	jniemann@mmwarburg.com
SALES TRADING		DESIGNATED SPONSORI	ING
Oliver Merckel	+49 40 3282-2634	Sebastian Schulz	+49 40 3282-2631
Head of Sales Trading Bastian Quast	omerckel@mmwarburg.com +49 40 3282-2701	Designated Sponsoring Jörg Treptow	sschulz@mmwarburg.com +49 40 3282-2658
Sales Trading	bquast@mmwarburg.com	Designated Sponsoring	jtreptow@mmwarburg.com
Christian Salomon Sales Trading	+49 40 3282-2685 csalomon@mmwarburg.com		
MACRO RESEARCH			
Carsten Klude Macro Research	+49 40 3282-2572 cklude@mmwarburg.com	Dr. Christian Jasperneite Investment Strategy	+49 40 3282-2439 cjasperneite@mmwarburg.com
Our research can be foun	nd under:		
Warburg Research res	search.mmwarburg.com/en/index.html	LSEG	www.lseg.com
Bloomberg	RESP MMWA GO	Capital IQ	www.capitaliq.com
FactSet	www.factset.com		
For access please contact:			
Andrea Schaper Sales Assistance	+49 40 3282-2632 aschaper@mmwarburg.com	Kerstin Muthig Sales Assistance	+49 40 3282-2703 kmuthig@mmwarburg.com